Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 30:8:649979.
doi: 10.3389/fmed.2021.649979. eCollection 2021.

Short-Term Outcomes of Refractory Diabetic Macular Edema Switch From Ranibizumab to Dexamethasone Implant and the Influential Factors: A Retrospective Real World Experience

Ning-Yi Hsia  1 , Chun-Ju Lin  1   2   3 , Huan-Sheng Chen  4 , Cheng-Hsien Chang  1   2   3 , Henry Bair  1   5 , Chun-Ting Lai  1 , Jane-Ming Lin  1   3 , Wen-Lu Chen  1   3 , Peng-Tai Tien  1   6 , Wen-Chuan Wu  1 , Yi-Yu Tsai  1   2   3
Affiliations

Short-Term Outcomes of Refractory Diabetic Macular Edema Switch From Ranibizumab to Dexamethasone Implant and the Influential Factors: A Retrospective Real World Experience

Ning-Yi Hsia et al. Front Med (Lausanne). .

Abstract

Introduction: To evaluate the effectiveness and safety of intravitreal dexamethasone (DEX) implants in refractory diabetic macular edema (DME) treated by intravitreal ranibizumab. Materials and Methods: We retrospectively analyzed DME patients who received DEX implant treatment after being refractory to at least 3 monthly intravitreal ranibizumab injections. The main outcomes were best-corrected visual acuity (BCVA), central retinal thickness (CRT), and intraocular pressure (IOP). Results: Twenty-nine eyes of 26 patients who had previously received an average of 8.1 ± 4.4 ranibizumab injections were included. Patients received between one and three DEX implants during 12.4 ± 7.4 months of follow-up. The mean final CRT significantly decreased from 384.4 ± 114.4 μm at baseline to 323.9 ± 77.7 μm (p = 0.0249). The mean final BCVA was 51.4 ± 21.3 letters, which was not significant compared to baseline (44.9 ± 30.2 letters, p = 0.1149). Mean IOP did not increase significantly. All patients tolerated the treatment well without serious adverse events. Higher baseline CRT and worse BCVA correlated with better therapeutic responses. Conclusion: Switching to DEX implant is feasible and safe for treating patients of DME refractory to intravitreal ranibizumab in real world. Further larger-scale or multicenter studies would be conducted to explore different DEX treatment strategies for DME, such as first-line or early switch therapy, for better BCVA improvement.

Keywords: diabetic macular edema; intravitreal dexamethasone implant; intravitreal ranibizumab; ozurdex; refractory diabetic macular edema.

PubMed Disclaimer

Conflict of interest statement

H-SC is employed by company NephroCare Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) Mean baseline and final CRT after the respective treatments. The mean final CRT after DEX implant treatment was significantly lower than the CRT (p = 0.0249) at baseline and 1 month after the last ranibizumab injection (p = 0.0265). (B) Mean best CRT (the lowest CRT value recorded during follow-up) at baseline and after the respective treatments. The mean best CRT after DEX implant treatment was significantly lower than the CRT (p < 0.0001) before treatment. *p < 0.05; **p < 0.001 compared to before-treatment data (Generalized linear mixed model).
Figure 2
Figure 2
(A) Mean BCVA at baseline and after the respective treatments. There was no significant improvement in BCVA 1 month after the last ranibizumab and after DEX implant treatment. (B) Mean maximal BCVA (the highest letter score recorded during follow-up) at baseline and after respective treatments. The mean maximal BCVA after DEX implant treatment was significantly higher than baseline BCVA (p = 0.0022). *p < 0.05 compared to before-treatment data (Generalized linear mixed model).
Figure 3
Figure 3
Correlation between changes in CRT and baseline CRT.
Figure 4
Figure 4
Correlation between changes in BCVA and baseline BCVA.
See this image and copyright information in PMC

References

    1. International Diabetes Federation . IDF Diabetes Atlas. 8th edn. Brussels: International Diabetes Federation; (2017).
    1. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. . Meta-Analysis for eye disease (META-EYE) study group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. (2012) 35:556–64. 10.2337/dc11-1909 - DOI - PMC - PubMed
    1. Cebeci Z, Kir N. Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant. Diabetes Metab Syndr Obes. (2015) 8:555–66. 10.2147/DMSO.S73540 - DOI - PMC - PubMed
    1. Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. (2015) 122:1375–94. 10.1016/j.ophtha.2015.03.024 - DOI - PubMed
    1. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. . Diabetic retinopathy clinical research network. aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. (2016) 123:1351–9. 10.1016/j.ophtha.2016.02.022 - DOI - PMC - PubMed